GLP-1 medications are a class of prescription drugs that mimic glucagon-like peptide-1, a hormone released naturally in the gut after eating. By activating GLP-1 receptors in the brain, pancreas, and digestive tract, these drugs reduce appetite, slow the rate food leaves the stomach, and help the pancreas release insulin in a blood-sugar-dependent way. The result is improved glycemic control in type 2 diabetes and, at higher doses, significant weight loss in people with obesity.

This article is for informational purposes only and does not constitute medical advice. Do not start, stop, or change any medication based on what you read here. See our full medical disclaimer and speak with a licensed healthcare provider about your individual situation.

Key Takeaways

  • GLP-1 receptor agonists work by mimicking a natural gut hormone that signals fullness, slows digestion, and stimulates insulin release.
  • Semaglutide (Ozempic, Wegovy, Rybelsus) and tirzepatide (Mounjaro, Zepbound) are the two most prescribed molecules as of 2026.
  • Tirzepatide is a dual GIP/GLP-1 agonist, which gives it a distinct and somewhat more potent mechanism than pure GLP-1 drugs.
  • Trial data show average weight loss of roughly 15 to 21% of body weight with weekly injections over 68 to 72 weeks.
  • An oral 25 mg semaglutide tablet (the Wegovy pill) was approved for weight management in late 2025 and launched in January 2026, the first GLP-1 pill cleared specifically for obesity.
  • The 2022 to 2024 supply shortages are over. The FDA declared the semaglutide and tirzepatide shortages resolved in early 2025, which ended the legal window for mass compounding of these drugs.
  • These are chronic-disease medications. Most of the weight lost returns within a year of stopping treatment, according to published follow-up data.
  • Emerging evidence supports cardiovascular and kidney-protective effects beyond blood sugar and weight control.

What Are GLP-1 Medications?

The simplest way to actually get this done

Superpower is a full-body lab membership that runs 100+ biomarkers, has each result reviewed by a doctor, and tracks your numbers year over year (about $199/year). It is what we point readers to when they would rather get one clean, complete draw than chase single tests one at a time. Here is superpower reviewed in full.

Check current Superpower pricing →

Glucagon-like peptide-1 (GLP-1) is an incretin hormone produced mainly in the L-cells of the small intestine and colon in response to food intake. Its job is to tell the body a meal has arrived: it stimulates pancreatic beta cells to secrete insulin, suppresses glucagon (which would otherwise raise blood sugar), and sends satiety signals to the hypothalamus. Natural GLP-1 is degraded by the enzyme DPP-4 within two to three minutes, so it has almost no lasting effect on its own.

GLP-1 receptor agonists (GLP-1 RAs) are synthetic molecules engineered to bind the same receptor but resist rapid breakdown. First-generation agents like exenatide and liraglutide (Victoza) established the class in the 2000s. The current wave, semaglutide and tirzepatide, represents a second generation with longer half-lives allowing once-weekly dosing and substantially greater efficacy.

How Do GLP-1 Drugs Actually Work in the Body?

The mechanism operates across three main systems at once.

Pancreatic effects. GLP-1 receptor activation stimulates insulin secretion strictly when blood glucose is elevated, which is why these drugs carry a low inherent risk of hypoglycemia compared with sulfonylureas. They also suppress glucagon, reducing the liver’s output of glucose between meals.

Gastric emptying. GLP-1 RAs slow the rate at which the stomach empties into the small intestine. Food sits longer in the stomach, producing a prolonged feeling of fullness and blunting the post-meal glucose spike. This is why nausea is one of the most common early side effects: the stomach is, physiologically, doing less of what it normally does quickly.

Central appetite suppression. GLP-1 receptors in the hypothalamus and brainstem respond to circulating drug levels by reducing hunger and increasing satiety. Research published in Nature Metabolism (2022) identified specific neurons in the hypothalamic arcuate nucleus that GLP-1 receptor activation directly inhibits appetite-driving pathways. This central effect is what drives the meaningful weight loss seen in trials, not just the slowed digestion.

What Makes Tirzepatide (Mounjaro, Zepbound) Different?

Tirzepatide is not a pure GLP-1 agonist. It is a dual agonist that activates both the GLP-1 receptor and the glucose-dependent insulinotropic polypeptide (GIP) receptor. GIP is the other major incretin hormone, released primarily from K-cells in the upper small intestine. For years, researchers debated whether adding GIP activity would help or hurt, because GIP was known to stimulate both insulin and glucagon. Eli Lilly’s SURMOUNT and SURPASS trial programs resolved the question decisively: the dual mechanism appears additive or synergistic rather than contradictory.

In the SURMOUNT-1 trial published in the New England Journal of Medicine (2022), participants on the 15 mg tirzepatide dose lost an average of 20.9% of body weight over 72 weeks, compared with a placebo loss of 3.1%. That places tirzepatide at the higher end of any approved anti-obesity medication to date. The SURPASS program showed similarly strong HbA1c reductions in type 2 diabetes, with the 15 mg dose achieving average HbA1c drops of approximately 2.3 percentage points in SURPASS-2.

The Main GLP-1 Medications: A Side-by-Side Overview

Below is a plain-language comparison of the four drugs most commonly discussed in clinical practice and media coverage. All require a prescription. Doses, approved indications, and contraindications differ, so this table is a starting point for a conversation with a provider, not a prescribing guide.

  • Ozempic (semaglutide 0.5, 1, 2 mg weekly injection): FDA-approved for type 2 diabetes management and cardiovascular risk reduction in adults with type 2 diabetes and established cardiovascular disease. Not FDA-approved for weight loss, though prescribed off-label for that purpose.
  • Wegovy (semaglutide 2.4 mg weekly injection): FDA-approved for chronic weight management in adults with obesity or overweight plus a weight-related condition. The SELECT trial (NEJM, 2023) found a 20% reduction in major cardiovascular events in people with pre-existing cardiovascular disease, leading to an expanded cardiovascular indication in March 2024.
  • Rybelsus (oral semaglutide 3, 7, 14 mg daily tablet): FDA-approved for type 2 diabetes. Lower bioavailability than injectable semaglutide, which is why the diabetes tablet tops out at 14 mg. Must be taken on an empty stomach with a small amount of plain water, 30 minutes before the first food or drink of the day.
  • Wegovy pill (oral semaglutide 25 mg daily tablet): The newest entry. The FDA approved a 25 mg once-daily oral semaglutide for chronic weight management in late 2025, and Novo Nordisk launched it in the United States in January 2026. In the OASIS 4 trial it produced about 16.6% mean weight loss among adherent participants, comparable to injectable Wegovy 2.4 mg. It removes the needle barrier but keeps the strict empty-stomach dosing rule, and unlike the injection it does not require refrigeration.
  • Mounjaro (tirzepatide 2.5 to 15 mg weekly injection): FDA-approved for type 2 diabetes. Also prescribed off-label for weight management before Zepbound’s approval.
  • Zepbound (tirzepatide 2.5 to 15 mg weekly injection): FDA-approved for chronic weight management in adults with obesity or overweight plus a weight-related condition. Same molecule as Mounjaro, different FDA indication and labeling. Approved November 2023.

What Do the Clinical Trials Actually Show?

The trial programs behind these drugs are among the largest obesity and diabetes studies ever conducted. Key numbers: in STEP 1 (NEJM, 2021), semaglutide 2.4 mg produced average weight loss of 14.9% over 68 weeks versus 2.4% with placebo, and 69% of participants on the drug lost at least 10% of body weight. In SURMOUNT-1 (NEJM, 2022), tirzepatide 15 mg achieved 20.9% average weight loss over 72 weeks. On the cardiovascular side, SUSTAIN-6 showed a 26% reduction in major adverse cardiovascular events with semaglutide versus placebo, and the SELECT trial (2023) replicated that finding at the weight-management dose in people without diabetes. The FLOW renal outcomes trial (NEJM, 2024) showed semaglutide reduced chronic kidney disease progression by 24%, prompting an expanded FDA indication in May 2024.

One thing worth saying plainly: these are group averages. Individual response varies widely. A minority of participants lost very little, while others exceeded 25% body weight loss. Baseline biology, adherence, dose reached, and lifestyle factors all influence outcome.

What to Expect: A Realistic Timeline

A common source of disappointment is a mismatch between expectations and the actual pace of these drugs. The schedule below describes the typical arc seen in the major trials, with the caveat that individual experience varies.

  • Weeks 1 to 4 (lowest dose): The starting dose is deliberately sub-therapeutic. Its purpose is tolerance, not weight loss. Many people notice a quieter appetite and reduced food preoccupation, sometimes called less “food noise,” but scale movement is usually small.
  • Weeks 4 to 16 (titration): The dose is stepped up roughly every four weeks. Weight loss becomes steadily more visible in this window, and blood sugar improvements in people with diabetes often appear within the first month or two.
  • Weeks 16 to 20 (therapeutic dose reached): Depending on the drug and tolerance, the maintenance dose is typically reached around this point. This is when the fuller effect begins to accumulate.
  • Months 6 to 18 (plateau approached): Weight loss continues but gradually slows, with most people approaching their plateau somewhere between 12 and 18 months. In STEP 1, the 14.9% average was measured at week 68; in SURMOUNT-1, the 20.9% figure was at week 72.

A useful clinical rule of thumb that has emerged in obesity medicine: if someone has reached the maintenance dose and lost less than roughly 5% of body weight by around month four to six, they may be a limited responder to that particular agent, and a provider might consider switching molecules or reassessing the plan.

What About Side Effects and Risks?

The most common side effects across all GLP-1 medications are gastrointestinal: nausea, vomiting, diarrhea, and constipation. In the STEP 1 trial, nausea affected roughly 44% of participants on semaglutide versus 16% on placebo, though most cases were mild to moderate and decreased over time as the body adjusted. Gradual dose escalation protocols exist specifically to reduce this burden.

More serious but rarer concerns include a risk of acute pancreatitis (seen at a low rate in trials and post-marketing data), and a black box warning for medullary thyroid carcinoma based on rodent studies. The FDA requires that all GLP-1 RAs carry this thyroid warning; the clinical significance in humans remains under study, but these drugs are contraindicated in anyone with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2.

For a thorough breakdown of individual drug risks, see our detailed guide to Ozempic side effects, which covers both common GI symptoms and the rarer adverse events documented in post-market surveillance.

Managing the Common Side Effects

Most of the gastrointestinal complaints are manageable and tend to fade as the body adapts. The single most effective tool is the dose-escalation schedule itself: starting at the lowest dose and stepping up only every four weeks gives the gut time to adjust. Beyond that, clinicians commonly advise eating smaller and slower meals, stopping at the first sign of fullness, cutting back on high-fat and very greasy foods that sit heavily in a slowed stomach, and staying well hydrated. Constipation often responds to added fiber and fluids. Persistent or severe symptoms are a reason to call the prescriber rather than push through, because a dose may need to be held or rolled back rather than advanced.

Does Rapid Weight Loss Cause Muscle Loss?

This is one of the most clinically important and underreported aspects of GLP-1 therapy. Rapid weight loss from any cause, including these medications, results in loss of both fat and lean muscle mass. Analysis of body composition data from STEP trials suggests that roughly 25 to 39% of total weight lost may be lean mass, a proportion similar to what is seen with other hypocaloric interventions but notable given the speed and magnitude of loss on semaglutide and tirzepatide.

Whether this muscle loss has meaningful functional consequences over the long term is actively debated. Resistance training during treatment appears to preserve lean mass, and several ongoing trials are studying combinations of GLP-1 medications with structured exercise programs. For a deeper look at the evidence and practical strategies, read our full coverage of muscle loss on GLP-1 medications.

What Happens When You Stop GLP-1 Medications?

The follow-up data here are unambiguous and clinically significant. In a withdrawal study published in Diabetes, Obesity and Metabolism (2022), participants who completed STEP 1 and then discontinued semaglutide regained on average 11.6 percentage points of the 17.3% weight they had lost, within 52 weeks of stopping. Blood pressure, blood sugar, and lipid improvements also largely reversed.

This is not a character flaw or a lack of willpower. It reflects the underlying biology: when the drug leaves the system, the appetite and metabolic set point it was suppressing reasserts itself. The analogy endocrinologists use more often now is that stopping a GLP-1 medication in obesity is like stopping a blood pressure medication in hypertension. The condition returns because the drug was treating an ongoing physiological state, not a temporary one.

Who Should Not Take GLP-1 Medications

These drugs are not appropriate for everyone, and a few contraindications are absolute. GLP-1 and dual agonists should be avoided by anyone with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2, the basis of the class-wide boxed thyroid warning. They are also contraindicated in people with a known serious hypersensitivity to the specific drug.

Several other groups warrant caution rather than a hard stop, with the decision left to a prescriber weighing individual risk. A history of pancreatitis raises concern given the rare pancreatitis signal. People prone to gallbladder disease should know that rapid weight loss of any kind increases the risk of gallstones. Those with gastroparesis or severe gastrointestinal disease may tolerate the slowed gastric emptying poorly. GLP-1 medications are not recommended during pregnancy or while trying to conceive, and current guidance is to stop them well before a planned pregnancy. People with type 1 diabetes, severe diabetic retinopathy, or a history of certain eating disorders also need individualized evaluation. Because these drugs slow digestion, they can also change how the body absorbs other oral medications taken at the same time.

Cost and Access in 2026

Cost remains the single biggest practical barrier for most people. List prices for the brand-name weight-management products have sat above roughly $1,000 per month before insurance and discounts, though what an individual actually pays varies enormously with coverage. Insurance for the weight-loss indication is inconsistent: many plans cover the diabetes versions while restricting Wegovy and Zepbound for obesity, and prior authorization is common.

The access picture has shifted since 2024. Both manufacturers now sell cash-pay options through their own direct channels, and a wave of telehealth platforms prescribe and ship brand-name GLP-1 medications to people who qualify, bundling the clinician visit, prescription, and delivery. Pricing, eligibility rules, and which specific product is offered differ widely between services. If you are comparing those options, our editors evaluated the leading providers on price transparency, what is actually prescribed, and ongoing support in our guide to the best GLP-1 telehealth services, and we separately map out the legitimate channels and the red flags in where to buy GLP-1 medication safely.

What Happened to Compounded GLP-1s?

During the 2022 to 2024 shortages, federal rules allowed pharmacies to compound their own semaglutide and tirzepatide because the brand-name drugs were officially in short supply. That window is now closed. The FDA declared the tirzepatide shortage resolved in December 2024 and the semaglutide shortage resolved in February 2025, and the grace periods for compounding both injections ended by mid-2025. The agency has since moved to keep these molecules off the lists that would permit large-scale compounding, citing a series of adverse-event reports tied to dosing errors with compounded multi-dose vials.

The practical upshot for 2026: the cheap compounded versions that proliferated during the shortage are largely no longer legally available from mainstream pharmacies, and online sellers still advertising “compounded” or “research” semaglutide warrant real caution. Products sold outside the regulated supply chain carry uncertain dosing and purity. The legitimate routes are now the brand-name products through a clinician, a pharmacy, or a vetted telehealth provider.

Frequently Asked Questions

What is the difference between Ozempic and Wegovy?

Both Ozempic and Wegovy contain the same active ingredient, semaglutide, but they are FDA-approved for different purposes and come in different dose ranges. Ozempic (0.5 mg, 1 mg, and 2 mg weekly injections) is approved for type 2 diabetes management and to reduce cardiovascular risk in adults with type 2 diabetes and established heart disease. Wegovy (up to 2.4 mg weekly injection) is approved specifically for chronic weight management in adults with obesity (BMI 30 or higher) or overweight (BMI 27 or higher) with at least one weight-related health condition. The higher dose in Wegovy is what drives the greater average weight loss seen in weight management trials compared with diabetes doses.

How long does it take GLP-1 medications to work?

Most people on GLP-1 medications notice reduced appetite within the first few weeks. Meaningful weight loss typically becomes visible by weeks 8 to 12, though the full effect accumulates over 12 to 18 months. In the STEP 1 trial of semaglutide 2.4 mg, participants lost an average of 14.9% of body weight over 68 weeks. Blood sugar improvements with Ozempic can appear within the first month. Doses are started low and increased gradually over several weeks to reduce gastrointestinal side effects, so the therapeutic dose is usually not reached until week 16 to 20 depending on the drug.

Who qualifies for a GLP-1 prescription?

For diabetes indications, GLP-1 medications are approved for adults with type 2 diabetes, typically when diet and exercise alone or metformin have not achieved adequate blood sugar control. For weight management, Wegovy and Zepbound are approved for adults with a BMI of 30 or higher, or a BMI of 27 or higher with at least one weight-related condition such as high blood pressure, type 2 diabetes, or high cholesterol. Rybelsus (oral semaglutide) is approved only for type 2 diabetes. A prescribing clinician evaluates individual medical history, contraindications such as a personal or family history of medullary thyroid carcinoma, and prior treatments before starting any GLP-1 medication.

Can you stop taking GLP-1 medications once you lose weight?

Clinical evidence shows that the weight lost during GLP-1 treatment is largely regained after stopping the medication. In a follow-up study published in Diabetes, Obesity and Metabolism (2022), participants who discontinued semaglutide 2.4 mg after the STEP 1 trial regained on average two-thirds of their prior weight loss within one year. This happens because the drugs address the physiological drivers of appetite and fat storage, not an underlying behavioral deficit. Many endocrinologists now describe obesity as a chronic condition requiring long-term treatment, similar to how statins are used continuously for high cholesterol rather than stopped once numbers improve. Discuss long-term plans with a prescriber before starting.

Is there a GLP-1 pill for weight loss now?

Yes. For most of the GLP-1 era the only oral option was Rybelsus, a daily semaglutide tablet approved only for type 2 diabetes. That changed in late 2025, when the FDA approved a higher-strength 25 mg once-daily oral semaglutide, marketed as the Wegovy pill, specifically for chronic weight management. Novo Nordisk launched it in the United States in January 2026, making it the first GLP-1 pill cleared for obesity. In the OASIS 4 trial it produced about 16.6% mean weight loss in adherent participants, broadly comparable to the injectable Wegovy 2.4 mg dose. The trade-off is the dosing discipline: like Rybelsus, it must be taken on an empty stomach with a small sip of water, 30 minutes before eating, drinking, or taking other medications.

Want a real clinician to run the numbers, not a guess?

Joi + Blokes is a telehealth clinic that prescribes GLP-1 medication (Zepbound, compounded semaglutide and tirzepatide), hormone therapy (TRT, HRT), thyroid care, and peptides after a real lab panel and clinician review, with no membership or consult fee (prescriptions from about $59/month, lab panels from $149). If the scale will not budge, this is where you find out whether insulin, thyroid, or hormones are the real reason. Here is Joi + Blokes reviewed in full.

See Joi + Blokes pricing →

Sources

All clinical claims in this article are grounded in peer-reviewed literature and regulatory documents. Key references are listed below.